*0011286985
*008190506s2018    xx#           000 0 nob
*019  $bk
*08230$a616.8522061
*100  $aHaugen, Tonje Owrenn$4aut$_150941600
*245  $aPsykofarmaka, psykisk lidelse og utviklingshemning$bet pasienteksempel
*246  $a[Psychopharmaceuticals, mental illness and developmental disability : example of a patient]
*300  $aS. 24-25, 30-35, 37 : ill.
*650  $aAtferdsvansker$2norart$_22014600
*650  $aangst$9nor$2norart$_128643000
*650  $aantipsykotika$9nor$2norart$_129712100
*650  $apsykisk utviklingshemmede$9nor$2norart$_128796100
*650  $apsykoser$9nor$2norart$_129442500
*653  $aantipsychotics$9eng$_131461900
*653  $aanxiety$9eng$_130114400
*653  $abehavioural problems$9eng$_137763800
*653  $adevelopmental disabilities$9eng$_134574000
*653  $apsychosis$9eng$_128828800
*700  $aBakken, Trine Lise$4aut$_131521300
*700  $aThorbjørnsen, Rune Aleksander;$4aut$_150941700
*700  $aWeiberg, Elise;$4aut$_150941800
*773  $tSOR rapport$gÅrg. 64, nr. 6 (2018)$x1500-8657$w(NO-LaBS)552683(tnr)
*999  $z1900641411$anorart:1900641411
^